The Claim
In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide results in a greater reduction in body weight (−11.6%) and glycated hemoglobin (−1.66 percentage points) over 36 months compared to dulaglutide (−4.8% and −0.88 percentage points, respectively), with equivalent cardiovascular safety.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Over 36 months, tirzepatide lowered body weight and blood sugar levels more than dulaglutide in adults with type 2 diabetes and heart disease, while both drugs had similar effects on cardiovascular safety.
See the scientific wording
Tirzepatide leads to a greater reduction in body weight (−11.6%) and glycated hemoglobin (−1.66 percentage points) compared to dulaglutide (−4.8% and −0.88 percentage points, respectively) in adults with type 2 diabetes and atherosclerotic cardiovascular disease over 36 months, indicating superior metabolic effects despite equivalent cardiovascular safety.
Tirzepatide activates two different receptors in the body that help the pancreas release more insulin when blood sugar is high, stop the liver from releasing too much sugar, and signal the brain to feel full sooner. This means less food is eaten, weight goes down, and blood sugar stays lower for longer.
What the research says
1 studyStudy: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
This study found that tirzepatide helped people with diabetes and heart disease lose more weight and lower their blood sugar better than dulaglutide, even though both drugs protected the heart equally well.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.